<div id="readability-page-1"><p><span>Medtronic (NYSE:MDT - Get Free Report)</span> had its price objective lifted by stock analysts at Stifel Nicolaus  from $90.00 to $105.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a &#34;hold&#34; rating on the medical technology company's stock. Stifel Nicolaus' price objective suggests a potential upside of 8.45% from the company's previous close.</p><ul><li>MarketBeat Week in Review – 08/18 - 08/22</li></ul><p>MDT has been the topic of a number of other reports. The Goldman Sachs Group dropped their price target on Medtronic from $82.00 to $81.00 and set a &#34;sell&#34; rating on the stock in a research report on Wednesday, October 1st. Wolfe Research raised Medtronic from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a research report on Monday, June 30th. Daiwa Capital Markets boosted their price target on Medtronic from $101.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, September 12th. UBS Group boosted their price target on Medtronic from $94.00 to $95.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, August 20th. Finally, Argus boosted their price target on Medtronic from $105.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, August 26th. One investment analyst  has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat, Medtronic  has an average rating of &#34;Moderate Buy&#34; and an average price target of $101.82.</p><p><b>Check Out Our Latest Research Report on MDT</b></p><h2>Medtronic Stock Down 1.1%</h2><ul><li>Medtronic: The Opportunity Gets Healthier for Income Investors</li></ul><p>Shares of MDT stock traded down $1.05 during midday trading on Thursday, reaching $96.82. 1,415,479 shares of the stock were exchanged, compared to its average volume of 7,597,098. Medtronic has a 1 year low of $79.29 and a 1 year high of $99.37. The company's 50 day moving average is $93.31 and its two-hundred day moving average is $88.65. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm has a market cap of $124.19 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78. </p><p>Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the business earned $1.23 EPS. The business's revenue for the quarter was up 7.7% on a year-over-year basis.  Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts predict that  Medtronic will post 5.46 EPS for the current year. </p><h2>Insider Buying and Selling at Medtronic</h2><ul><li>5 Robotics Stocks to Buy for the Future of Automation</li></ul><p>In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company's stock, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is owned by corporate insiders. </p><h2>Institutional Investors Weigh In On Medtronic</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. 1248 Management LLC purchased a new stake in shares of  Medtronic in the 1st quarter worth $26,000.  Delos Wealth Advisors LLC purchased a new stake in shares of  Medtronic in the 2nd quarter worth $27,000.  Columbia River Financial Group LLC purchased a new stake in shares of  Medtronic in the 1st quarter worth $28,000.  Twin Tree Management LP purchased a new stake in shares of  Medtronic in the 1st quarter worth $29,000.  Finally, Activest Wealth Management increased its stake in shares of  Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock worth $30,000 after purchasing an additional 322 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Medtronic Company Profile</h2> (Get Free Report)<p>Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Medtronic</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>3 High P/E Stocks Justified by Future Upside Potential</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale?</li><li>With Risk Tolerance, One Size Does Not Fit All</li><li>Adobe Launches Premiere Pro on iPhone, Upside Ahead?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medtronic Right Now?</h2><p>Before you consider Medtronic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Stifel Nicolaus has raised its price target for Medtronic (NYSE:MDT) from $90.00 to $105.00, maintaining a "hold" rating. This suggests an 8.45% potential upside from the previous close. Other analysts have varied opinions, with Goldman Sachs lowering their target to $81.00 (sell rating) and Argus increasing theirs to $115.00 (buy rating). Medtronic's stock recently traded down 1.1% to $96.82, with a market cap of $124.19 billion and a PE ratio of 26.68. The company reported $1.26 EPS for the last quarter, exceeding estimates.</p>

Stifel Nicolaus Forecasts Strong Price Appreciation for Medtronic (NYSE:MDT) Stock